Sign in
4

Changes in Ownership

Cartesian Therapeutics, Inc. Filed Acc 0001453687-24-000132

Chief Technology Officer sold 82,368 shares at an average $17.46 ($1,438,038)

  • Chief Technology Officer acquired 82,368 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Kurtoglu Metin Chief Technology Officer 2024-11-14 Option exercise +25,900 $1.41 $36,519 76,933 D
Kurtoglu Metin Chief Technology Officer 2024-11-14 Sale −21,900 $16.33 $357,645 55,033 D
Kurtoglu Metin Chief Technology Officer 2024-11-14 Sale −4,000 $17.06 $68,256 51,033 D
Kurtoglu Metin Chief Technology Officer 2024-11-15 Option exercise +22,068 $1.41 $31,116 73,101 D
Kurtoglu Metin Chief Technology Officer 2024-11-15 Sale −22,068 $17.20 $379,497 51,033 D
Kurtoglu Metin Chief Technology Officer 2024-11-18 Option exercise +34,400 $1.41 $48,504 85,433 D
Kurtoglu Metin Chief Technology Officer 2024-11-18 Sale −16,672 $18.19 $303,212 68,761 D
Kurtoglu Metin Chief Technology Officer 2024-11-18 Sale −17,728 $18.58 $329,429 51,033 D
Derivatives
Kurtoglu Metin Chief Technology Officer 2024-11-14 Option exercise · Stock Option (Right to Buy) −25,900 187,920 D
Kurtoglu Metin Chief Technology Officer 2024-11-15 Option exercise · Stock Option (Right to Buy) −22,068 165,852 D
Kurtoglu Metin Chief Technology Officer 2024-11-18 Option exercise · Stock Option (Right to Buy) −34,400 131,452 D
Open-market sales · 82,368 sh · avg $17.46 · $1,438,038
Loading xslF345X05/wk-form4_1731976349.xml…